% | $
Quotes you view appear here for quick access.

Bio-Path Holdings, Inc. Message Board

  • petersengary37 petersengary37 Jun 12, 2012 10:21 AM Flag

    Time to buy

    This isn't my first Bio-tech, but I believe this is the future of cancer treatment. I am buying more shares today. The phase one results are promising and the next cohort will get 40mggm/m2 which is near the expected recommended dose. If these results are good without toxicity it will be on to Phase two. This 40 cent stock will explode! It is still speculation but it looks good.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • More information from the detailed report.

    • I fail to see the hype. Read the news release.

      The new web-site URl I posted earlier explains the difference between cationic antisense delivery and BPTH nuetral delivery system. The lack of side effects, if drug is proven effective, is the key IMO.

      • 1 Reply to sjstockshark
      • It appears the company is trying to get the word out...


        Bio-Path Holdings, Inc., (BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will present a company overview at the 2012 Southern California Investor Conference in Newport Beach, Calif., on Thursday, August 30, 2012, at 3:00 p.m. Pacific Time.

        A webcast of Mr. Nielsen’s remarks will be available live. You can access the webcast at the Company’s website:

    • This was their comment in the latest release. It basically is saying that it is working as well or better than expected!

      As previously reported, the Company added new suppliers for the Grb-2 drug substance and for the final drug product in order to increase the capacity of its drug supply chain. The necessity for increased drug supply is based on the experience with treating patients in Cohort 3 of the clinical trial, when all three patients benefited from treatment with Liposomal Grb-2 and, in the opinion of the principal investigator, were stabilized. Based on this initial success, the need for additional drug requirements for Cohort 4 and beyond has increased significantly. The first batch of drug from the new supply chain was delivered to the Company in July of 2012.

1.34-0.07(-4.96%)May 27 4:00 PMEDT